Tenaya Therapeutics Extends Runway with $56M Financing as Gene Therapy Data Shows Promise — Tenaya Therapeutics, Inc.

Event summary

Tenaya Therapeutics reported promising data for TN-201 and TN-401 gene therapies in Q4 2025, with plans for additional data readouts and regulatory alignment in 2026.
New preclinical data supports TN-301’s potential in multiple indications, including Duchenne Muscular Dystrophy (DMD).
Entered into a multi-target research collaboration with Alnylam Pharmaceuticals, receiving up to $10M upfront and potential milestone payments totaling up to $1.1B.
Closed a December 2025 financing round with net proceeds of $55.8M, extending cash runway into the second half of 2027.

The big picture

Tenaya Therapeutics is positioning itself as a leader in gene therapy for cardiac conditions, leveraging promising clinical data and strategic partnerships to extend its cash runway. The company's focus on addressing the underlying causes of heart disease aligns with broader industry trends toward precision medicine and genetic therapies. With $56M in new financing and potential milestone payments from Alnylam, Tenaya aims to accelerate the development of its pipeline, including TN-201 for hypertrophic cardiomyopathy (HCM) and TN-401 for arrhythmogenic right ventricular cardiomyopathy (ARVC).

What we're watching

Regulatory Alignment: Whether Tenaya can secure regulatory alignment for pivotal trial plans for TN-201 and TN-401 by the end of 2026.
Clinical Data Readouts: The pace at which additional data from MyPEAK-1 and RIDGE-1 trials will be released in 2026.
Pipeline Expansion: How the collaboration with Alnylam Pharmaceuticals will impact Tenaya’s ability to identify and validate novel genetic targets for cardiovascular disease.